title: Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study.
abstract: BACKGROUND
  Eslicarbazepine acetate (ESL, Aptiom®) is a once-daily (QD) anticonvulsant, approved as adjunctive treatment of partial-onset seizures (POS). It is extensively converted after oral administration to eslicarbazepine, and is believed to exert its effect through inhibition of voltage-gated sodium channels. The possible role of ESL as monotherapy to treat POS has not yet been established.
  
  
  METHODS
  This study was an 18-week, multicenter, randomized double-blind trial of gradual conversion to ESL monotherapy in adults with POS not well controlled by 1-2 antiepileptic drugs (AEDs), using historical data as the control. The study comprised an 8-week baseline period, a 2-week titration period, a 6-week AED conversion period, a 10-week monotherapy period, and either a 1-week taper period or optional entry to an open-label extension study. The primary endpoint compared the Kaplan-Meier (KM)-estimated 112-day exit rate with a threshold value calculated from the historical controls.
  
  
  RESULTS
  There were 172 randomized patients; 154 (90%) entered the AED conversion period and 121 (70%) completed the study. The KM-estimated exit rates [confidence interval (CI)] were 15.6% [8.1-28.7%] for ESL 1200 mg, and 12.8% [7.5-21.5%] for ESL 1600 mg. The upper limits of the 95% CI KM-estimates were below the pre-specified threshold for historical control of 65.3%, indicating that ESL was efficacious in reducing seizure-related exits, compared with historical control. During the 18-week double-blind treatment period, median reductions in standardized seizure frequency occurred with ESL 1200 mg (36.1%) and ESL 1600 mg (47.5%). The responder rates (a 50% or greater reduction in seizure frequency from baseline) during the 18-week double-blind period and the monotherapy period, respectively, were 35.2% and 38.9% for ESL 1200 mg, and 46.0% and 46.0% for ESL 1600 mg. The overall adverse event profile was consistent with the known safety profile of ESL.
  
  
  CONCLUSIONS
  These findings indicate that ESL monotherapy (1200 and 1600 mg QD) was efficacious and well tolerated in this study.
  
  
  BACKGROUND
  NCT01091662 ; EudraCT No. 2010-018684-42.
authors.affiliation: Department of Neurology, Temple University School of Medicine, Philadelphia, PA, USA. mercedes.jacobson@tuhs.temple.edu.
authors.forename: Mercedes P
authors.initials: MP
authors.lastname: Jacobson
authors.affiliation: CTC Rychnov nad Kněznou s.r.o, Rychnov nad Kneznou, Czech Republic. pazdera@neurol.cz.
authors.forename: Ladislav
authors.initials: L
authors.lastname: Pazdera
authors.affiliation: Neuro-Pain Medical Center, Fresno, CA, USA. neuro736@gmail.com.
authors.forename: Perminder
authors.initials: P
authors.lastname: Bhatia
authors.affiliation: Sunovion Pharmaceuticals Inc., Marlborough, MA, USA. todd.grinnell@sunovion.com.
authors.forename: Todd
authors.initials: T
authors.lastname: Grinnell
authors.affiliation: Sunovion Pharmaceuticals Inc., Marlborough, MA, USA. hailong.cheng@sunovion.com.
authors.forename: Hailong
authors.initials: H
authors.lastname: Cheng
authors.affiliation: Sunovion Pharmaceuticals Inc., Marlborough, MA, USA. david.blum@sunovion.com.
authors.forename: David
authors.initials: D
authors.lastname: Blum
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000927:Anticonvulsants / Q000627:therapeutic use*; D003984:Dibenzazepines / Q000627:therapeutic use*; D004311:Double-Blind Method; D004828:Epilepsies, Partial / Q000188:drug therapy*; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D012640:Seizures / Q000188:drug therapy; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000927:Anticonvulsants; D003984:Dibenzazepines; C416835:eslicarbazepine acetate